CD8A and COVID-19: Notably, both of these studies reported heterogeneity in T‐cell activation in COVID‐19 patients and provided evidence that both CD4+ and CD8+ T cells are capable of mounting potent immune responses with potential emergence of impaired or excessive T‐cell responses.